Podcasts about pharmaceutical sciences

“Don't go where the path may lead. Go instead where there is no path and leave a trail.” This was the sage advice shared by Dan Jenkins with the 10 teams participating in the grand finale of the 2026 Stella Zhang New Venture Competition, housed in UC Irvine's Paul Merage School of Business. The event is in its 22nd year, and Jenkins has been one of its co-chairs since 2014. He's also an honorary board member for UC Irvine's Beall Center for Innovation and Entrepreneurship, whose faculty director, Imran Currim, offered this additional thought about the competition: “It takes a village.” That village is populated by many people, including myriad sponsors, volunteers who act as mentors and judges, and the contestants themselves: teams consisting of students, faculty, researchers, staff and community members who are enthused to launch a startup and turn their idea into a real business. We're shining a spotlight on the Stella Zhang New Venture Competition in this episode of The UC Irvine Podcast. We'll speak with Sakhi Patel, a graduate student in UC Irvine's School of Pharmacy & Pharmaceutical Sciences, whose lived experiences inspired her team's business, CuraVoice. We'll also hear from Alicia Rantos and Ernie Rapp, two of the event's 160 volunteer coaches and judges. And we'll take listeners inside the Merage School's SB1 Auditorium on May 21, when the finalists presented their pitches to dazzle the panel and audience and win prize money that could help them achieve their goals. “Blazing Nights of Light,” the music featured throughout this episode, was provided by The Whole Other via the audio library in YouTube Studio.

For this Managed Care Cast episode, The American Journal of Managed Care® (AJMC®) spoke with Anuraag R. Kansal, PhD, who leads health economics research at GRAIL, about his study, “State Medicaid Budgetary Implications of New Cancers," published in the July 2026 issue; it examined how new cancer diagnoses affected state Medicaid budgets. He conducted the study with Amanda C. Chen, PhD, of the USC Mann School of Pharmacy and Pharmaceutical Sciences, and David C. Grabowski, PhD, of Harvard Medical School. Kansal explained to AJMC that despite Medicaid's younger population, cancer remains the third-largest source of program spending. Most existing research had focused on commercial and Medicare populations rather than Medicaid specifically. Consequently, using de-identified CMS claims data, he and his team identified new cancer diagnoses, defined as no prior cancer evidence in the preceding 6 months, and compared spending, hospitalizations, and emergency department use between metastatic and non-metastatic cases. Kansal highlighted the core finding, which was that metastatic diagnoses were associated with significantly higher spending than non-metastatic diagnoses across most cancer types. Notably, health care utilization patterns were consistent between fee-for-service and capitated Medicaid states, suggesting that cost drivers stemmed from the disease itself, particularly the shift to systemic therapies once cancer spread, rather than from program administration models. Kansal pointed to the 4 cancer screenings recommended by the US Preventive Services Task Force, namely lung, breast, colorectal, and cervical, as opportunities to reduce late-stage diagnoses and their associated costs while noting that cancers without established screening protocols presented a distinct policy challenge. On balancing innovative treatment access with cost sustainability, he emphasized that Medicaid's state-by-state administration means that no single policy solution applied universally. Still, Kansal emphasized that earlier detection could offer states greater financial flexibility to support innovative therapies for patients with true clinical need. “Intervening earlier is one of the opportunities we might have to really make a difference,” he concluded.

On this episode of White Coat Radio, we welcome Dr. Morteza Rasoulianboroujeni, who joined East Tennessee State University Bill Gatton College of Pharmacy as an Assistant Professor of Pharmaceutical Sciences in July 2025. Prior to joining ETSU, he earned his Ph.D. in Pharmaceutical Sciences and completed postdoctoral training at the University of Wisconsin–Madison. His research focuses on developing drug delivery systems, with particular emphasis on improving the formulation and biodistribution of nanomedicines for cancer treatment. Full transcription: 00;00;09;20 - 00;00;39;10 Morteza Rasoulianboroujeni  The very first thing that impressed me with, about ETSU what people and the culture we have here. And I got to join ETSU. And here I am. 00;00;39;13 - 00;01;02;20 Michele Williams Welcome to White Coat Radio, a podcast from East Tennessee State University. Bill Gatton College of Pharmacy in Johnson City, Tennessee. Each episode we cover a wide range of topics about the pharmacy school experience, from study tips to deep dives with faculty and student pharmacists. I'm one of your host Dr. Michelle Williams, assistant professor and director of academic success. 00;01;02;22 - 00;01;29;04 Stephen Woodward And I'm Stephen Woodward, marketing and communications manager. Today we welcome Dr. Morteza Rasoulianboroujeni, who joined Gatton as an assistant professor in pharmaceutical sciences in July of 2025. Prior to ETSU, he earned his PhD in pharmaceutical sciences and completed post-doctoral training at the University of Wisconsin-Madison. His research focuses on the development of drug delivery systems, with particular emphasis on improving formulation and bio distribution of nanomedicine for cancer treatment. 00;01;29;06 - 00;01;35;05 Stephen Woodward Dr. Rasoulian welcome to White Coat Radio. We're so glad you're here. And would you mind just introduce yourself? 00;01;35;08 - 00;01;55;00 Morteza Rasoulianboroujeni  Oh, thank you so much. I'm very excited and very happy to be here. Thanks for inviting me. My name is. My first name is Morteza. My last name is Rasoulian. People here in the school may see my the long version of my last name, which is indeed. I'm going to take this opportunity to explain why my last name is so. 00;01;55;02 - 00;01;57;21 Michele Williams Thank you for that, by the way. 00;01;57;23 - 00;02;20;11 Morteza Rasoulianboroujeni  So my my last name is Rasoulian. So students can feel free to call me with that last name. The second part of what you see in my last name is actually the city I was born in. So there should be space between the two. But, because it might be confused with a middle name versus a last name, if someone puts a space in between the two. 00;02;20;14 - 00;02;47;01 Morteza Rasoulianboroujeni  That's why we try to kind of keep the two words together. So Boroujeni is my last name and which is the city I was born in. I got my PhD at University of Wisconsin-Madison and joined Gatton College of Pharmacy in July 2025 as an assistant professor. And I'm very glad to be here. I'll be happy to kind of talk about more more about my background that sounds great. 00;02;47;03 - 00;02;57;24 Michele Williams That does sound great. And we're really, really happy to have you here. And, tell us a little bit about your the career path that led you to Gatton. 00;02;57;26 - 00;03;26;02 Morteza Rasoulianboroujeni  Sure. That's a very good question, because I sometimes think about kind of how I got here and kind of, like, chose this, career and becoming a faculty. It's a long story, but if I'm going to start from the very beginning, I was always very interested in working in healthcare, things like including biotech, but I was I was also very, very good at math. 00;03;26;05 - 00;04;01;18 Morteza Rasoulianboroujeni  So when I wanted to start my undergrad program, I was always thinking I wanted to be an engineer because I've, like, been good at math. But I really loved biology and the application of all those kind of things in biology. So I decided to go for a biomedical engineering program. So that was my undergrad background. And then later, in my kind of experience in at the university, I learned more about drug delivery, which is, one of the fields that biomedical engineers work on and also pharmaceutical scientists. 00;04;01;21 - 00;04;46;29 Morteza Rasoulianboroujeni  And I kind of like I can say, I fell in love with that, with that field to kind of work on it. And I joined several labs to, to kind of work on different aspects of this. I've worked for Marquette University School of Dentistry for a while before I start my PhD, and there was a biomaterials lab over there that I work and I learned that I want to take my research experience to the next level and start a research based career, which for me in, in that time was either becoming a faculty and have my own research program, or joining a biotech company, like a pharmaceutical company. 00;04;47;02 - 00;05;13;23 Morteza Rasoulianboroujeni  And for both, a PhD could be the route to kind of get there. So I started applying for it for graduate schools. I joined the University of Wisconsin, and I did my PhD there. It might be very interesting, if you know that before the end of my PhD, like I was, I was I was applying and getting interviewed by pharmaceutical companies, like Merck and Johnson and Johnson. 00;05;13;26 - 00;05;50;26 Morteza Rasoulianboroujeni  But during the interviews and doing more research, I started to think that is it. What I'm going to do long term, kind of. It was it was very attractive for me because they deal with the end product that at the next step goes to market or, into the clinic and kind of helps patients. But at the same time, you know, as you get to that level of quality control, CMC manufacturing and all those kind of things, you can have less of innovative research and initiating new projects and kind of have that freedom to work on whatever you excites you. 00;05;51;01 - 00;06;19;15 Morteza Rasoulianboroujeni  And it more like you have to stick to very, serious and well established standards. Right? So then I was like, okay, maybe I'm interested in a research, but maybe more like early stage innovative kind of research. And that's when I decided to join a startup company. So during the last year of my PhD and early days are postdocs I worked with a startup company in San Francisco for a while. 00;06;19;15 - 00;06;49;26 Morteza Rasoulianboroujeni  I was between like flying between Madison and San Francisco. Oh my. For a long time. And then over there. It was exciting to do this kind of research, because that was at at the interface of kind of introducing a new technology and commercialize that. Right? I'm still very interested in that. But what I also learned is that I like to stand here, but I also want to be able to initiate new ideas to feed into this pipeline. 00;06;50;03 - 00;07;17;14 Morteza Rasoulianboroujeni  So after finishing my postdoc, I learned that a faculty position in, School of Pharmacy can help me do that. That's why I was like, I'm going to apply for faculty positions while also keeping in touch with the startup companies in order to translate my research to, to, to a startup companies and later as a product. So applying for, pharmacy schools to become a faculty. 00;07;17;17 - 00;07;34;21 Morteza Rasoulianboroujeni  I got familiar with Etsu. I interviewed here the very first thing that impressed me with, about Etsu, where people and the culture we have here. And I got to join Etsu, and here I am. 00;07;34;24 - 00;07;39;14 Stephen Woodward So that's great. We hear that so much about the culture. And the people here are definitely people first. 00;07;39;17 - 00;07;52;26 Michele Williams Yeah, and you fit right in. Yeah, too. Thank you. Yeah, I can remember when when you came for your interview. We we, either went out to once at breakfast or or lunch or dinner, I can't remember. 00;07;52;26 - 00;07;56;08 Morteza Rasoulianboroujeni  I think it was. Yeah, I think it was dinner. 00;07;56;10 - 00;08;00;17 Michele Williams I think I remember thinking that you would be a good fit. 00;08;00;20 - 00;08;30;29 Morteza Rasoulianboroujeni  Yeah. Thank you. Yeah, yeah, it was great when when I visited here, like, Etsu had all that research infrastructure that I had. I heard about their plans to further develop this. Yeah. I loved the support of the leadership for research and the plans they have to kind of develop this further. And I also thought it also gives me the freedom to kind of work at this interface of focusing on my own research, while also working with startup companies to try to transition that. 00;08;30;29 - 00;08;54;00 Morteza Rasoulianboroujeni  And actually, right now I work with, the office of, research and sponsor programs. Really, kind of I, I joined their that the trainings and all that resources they have for, for, filing a patent for example, how you can spin out the startup, from the university. You know, Etsu is moving toward that direction. I can contribute to that. 00;08;54;01 - 00;08;55;16 Morteza Rasoulianboroujeni  That's awesome. Yeah. 00;08;55;18 - 00;09;04;29 Stephen Woodward Well, I could tell you connected well with the students, too, because it will be in retreat. I mean, out of the gate. You were playing volleyball and everything, and and so it was really nice. Got some good pictures of my day. 00;09;05;00 - 00;09;16;25 Morteza Rasoulianboroujeni  Yeah. Thank you for that. They they are the best picture salon has ever taken. Oh yeah. Yeah. No, it was the moments, you know, you thought. 00;09;16;27 - 00;09;22;19 Stephen Woodward Yeah well it's great along those lines. And what classes can students expect to see you school. 00;09;22;21 - 00;09;47;26 Morteza Rasoulianboroujeni  For the current semester and all the spring semesters? I'm going to be teaching in pharmacology to, and I'm going to be covering the oncology part like oncology drugs, because that's also part of my research. We can talk about it more. But yeah, I focus on cancer and treating cancer for my research. And I'm going to be teaching oncology drugs, for pharmacology too. 00;09;47;28 - 00;10;19;03 Morteza Rasoulianboroujeni  In fall semesters I'm going to be teaching pharmacology. One. And in that course I mainly cover antibiotics. And that longer term plan is also for me to cover to, to instruct, PCA. So yeah, right now, I'm joining Doctor Lugo's classes to kind of see the structure of the course, while also we have another course which is called advanced PCA, and that's for graduate students. 00;10;19;03 - 00;10;29;19 Morteza Rasoulianboroujeni  That's a three credit course, which I take care of, one extra credit for graduate students. So right now I'm teaching also in advanced PCA for graduate students. 00;10;29;19 - 00;10;30;21 Michele Williams And PCA is for. 00;10;30;28 - 00;10;34;03 Morteza Rasoulianboroujeni  Some other kinetics. Sorry. Yeah I yeah, some of the kinetic. 00;10;34;05 - 00;10;37;17 Michele Williams So there's an advanced PCA strategies that. 00;10;37;17 - 00;10;40;08 Morteza Rasoulianboroujeni  Yeah. 00;10;40;10 - 00;10;52;26 Michele Williams So you mentioned your research and I understand that students can work with you definitely research, which is very exciting. So can you give an example of the kind of research that students can do with you? 00;10;52;27 - 00;11;29;07 Morteza Rasoulianboroujeni  Sure. I, I'm, I have just begun, establishing my research programs, my research program. I'm going to have two research programs. One of them and and both of them are going to be about nanomedicine. The first one, which is mainly focused on lipid nanoparticles, which are nanoparticles used for in the formulation of Covid vaccines. They are used to package mRNA or other genetic material for gene delivery application, or of course vaccine application. 00;11;29;07 - 00;11;55;09 Morteza Rasoulianboroujeni  So these nanoparticles are very complicated to design. And the reason for that is that we do not have enough knowledge about how they structure properties, relationship between what we use in making these nanoparticles and what they can do in the body works. Right. So if, for example, we're going to shoot for a certain application, which is let's say producing insulin for diabetes, right? 00;11;55;09 - 00;12;23;12 Morteza Rasoulianboroujeni  So we need to be able to target these nanoparticles with an mRNA for example, in it to their pancreas. Right. So pancreatic tissue but no one knows how you can kind of, decide about formulation components and how you can mix them in order to, kind of control the bio distribution in the body and target them toward pancreatic, pancreatic tissue or any tissue of interest. 00;12;23;15 - 00;12;49;09 Morteza Rasoulianboroujeni  But we know that there's a correlation between the two. What I'm trying to do in my research is using artificial intelligence AI to establish this structure. Property relationships, because we can have data for formulation and we can have data for the final response, which is, for example, accumulation in a certain tissue or, entering the cell or expressing a certain protein, whatever it is. 00;12;49;10 - 00;13;18;27 Morteza Rasoulianboroujeni  So we're trying to establish AI models for these lipid nanoparticle design and have an AI guided design of lipid nanoparticles. So because this doesn't need that lab work at this point and is more computational, I have already initiated that program. And actually I have some student faculty students already involved in that project. And then the second, like at some point when we use AI to design these lipid nanoparticles, we will try them in real world, like in vet lab. 00;13;18;27 - 00;13;42;01 Morteza Rasoulianboroujeni  So we will formulate what I suggest us to formulate. And then we administer them like we inject them to animals to see whether they work the way they're supposed to work, as AI is guiding us in that direction. So that's one of the research programs. And the longer term goal is this the second research program I'm trying to establish, but it needs an extra, some extra time, to get there. 00;13;42;01 - 00;13;57;22 Morteza Rasoulianboroujeni  Where we can initiate this project is on cancer and nanomedicine, which we use polymeric nanoparticles to encapsulate chemo drugs and change their pharmacokinetic and bio distribution in order to reduce the side effects and increase the efficacy. 00;13;57;28 - 00;14;02;04 Michele Williams So they go straight to the place that they need to treat versus going out into the. 00;14;02;08 - 00;14;03;23 Morteza Rasoulianboroujeni  Exactly. That's the. 00;14;03;25 - 00;14;04;11 Michele Williams Places. 00;14;04;11 - 00;14;30;06 Morteza Rasoulianboroujeni  That's the goal. Yes. Thinking about oncology drugs and chemo, a lot of them are hydrophobic. And students who have, who have tech, who are taking, pharmacokinetic course or they know that they distribute all over the body. So when this drug, which is super toxic, is all over the body, it kills all the healthy cells as well as is killing cancer cells. 00;14;30;06 - 00;14;52;08 Morteza Rasoulianboroujeni  It's not it has some selectivity mechanisms associated with it, but it's not super selective to what cancer cells. And that's what why you see these side effects. So for patients who are treated with chemotherapy, what we're trying to do is that to encapsulate this in a nanoparticle, and sometimes we add a targeting ligand on the surface of these nanoparticle. 00;14;52;14 - 00;15;14;21 Morteza Rasoulianboroujeni  That targeting moiety targeting agent can attach to cancer cells and or cancer tissue more efficiently that it can attach to healthy tissue. So we expect that after injecting, we see more nanoparticles in cancer tissue and no less or no nanoparticle in other tissues. And that way we improve efficacy and we reduce toxicity. 00;15;14;25 - 00;15;23;22 Michele Williams That's amazing. Yeah. So if a student is interested in working with you on your research, what do they need to do? Kind did just. 00;15;23;22 - 00;15;24;19 Morteza Rasoulianboroujeni  Reach out to me. 00;15;24;19 - 00;15;25;23 Michele Williams And they can email. 00;15;25;23 - 00;15;48;02 Morteza Rasoulianboroujeni  Me. Yes, definitely. I'm very open to kind of very direct communication. And that's what we're doing right now. ... And that, that that's what happened. The current students we have in the lab, they reach out, reach out to me directly, and they express interest in my research. I talk to them, in, in several meetings, and I even present my research in the PowerPoints that I have. 00;15;48;02 - 00;16;25;28 Morteza Rasoulianboroujeni  So they have an idea. They know I work on nanomedicine, but they may not be familiar with the details of what I'm doing. So I introduce all those details, first and then if they, still express the interest, I'll share with them several papers to read. And if they continue being interested, then I ask them to sign up for a research elective, for example, if that helps them to also manage their coursework and and credit, for research, and if even if they are interested in to kind of do it beyond just research electives, I'm very open to that and I'll be very happy to work with them. 00;16;26;00 - 00;16;27;16 Michele Williams That's great. Yeah, yeah, yeah. 00;16;27;20 - 00;16;33;07 Stephen Woodward What kind of tools in your lab do you use to manipulate these nanoparticles? Yeah. 00;16;33;07 - 00;17;01;20 Morteza Rasoulianboroujeni  So these nanoparticles are made by, by many different ways. But what we try to do to use principles of just mixing different agents, including organic solvent with aqueous, solvent. I can give you an example. You have seen have you ever added oil to water? For sure. You've done what happens? Like if you mix it so like harsh it becomes small. 00;17;01;20 - 00;17;03;08 Michele Williams Droplets little pellets. 00;17;03;08 - 00;17;25;21 Morteza Rasoulianboroujeni  Yeah. So let let let's say we do this. We have a polymer which is a piece of plastic but it's biodegradable inside the body. And we dissolve it in a solvent which is hydrophobic, meaning that it doesn't like to mix with water like oil. Right. And we we choose the solvent to be very volatile, meaning that it evaporates very fast. 00;17;25;23 - 00;17;53;11 Morteza Rasoulianboroujeni  It leaves that whatever you have, like the beach or the glass, container that you have. So if we put the polymer and the drug in that organic solvent oil, and we add it to water and we mix it harsh, and while we're mixing, we allow the organic solvent to leave the container because it's volatile. What happens is that the particles solidify and while they're solidify, they encapsulate the drug in them. 00;17;53;14 - 00;17;58;22 Morteza Rasoulianboroujeni  And then we separate them. And these nanoparticles now can be used for like injection. 00;17;58;27 - 00;18;01;02 Michele Williams And so they're very, very tiny. 00;18;01;02 - 00;18;29;28 Morteza Rasoulianboroujeni  Yeah. They're very tiny nano size like tat. If you let me think about it, how I can, you know, give you an A scale so they 10 to -7m, which is like if you put together 1 million of them, right? 1 million of these particles, it's going to be, ten centimeters or like two, three inches. 00;18;30;00 - 00;18;30;19 Michele Williams Oh, wow. 00;18;30;21 - 00;18;31;17 Morteza Rasoulianboroujeni  So that's. 00;18;31;17 - 00;18;31;29 Michele Williams A little. 00;18;32;06 - 00;18;48;19 Morteza Rasoulianboroujeni  Million of them. Yeah. You put next to each other. So, these nanoparticles should be and that should be the case because when we inject them the blood, if they're large, they lead to very adverse reactions, like the body recognizes them as foreign. 00;18;48;21 - 00;18;52;19 Michele Williams You can't have them in your tissue or in your blood vessels if it's too big. 00;18;52;19 - 00;19;00;07 Morteza Rasoulianboroujeni  Yes, yes, it blocks like the capillary. So that's why they should be very small to pass through all these, like. Yeah. The. 00;19;00;07 - 00;19;02;03 Michele Williams Typical plastic journey. Yeah. 00;19;02;05 - 00;19;03;12 Stephen Woodward Yeah. 00;19;03;15 - 00;19;04;16 Morteza Rasoulianboroujeni  Yeah. 00;19;04;19 - 00;19;05;10 Michele Williams That's amazing. 00;19;05;10 - 00;19;12;18 Stephen Woodward Yeah. This has been an incredible conversation. Is there is there anything else you'd like to tell us about your research or anything. 00;19;12;21 - 00;19;39;13 Morteza Rasoulianboroujeni  So the way so let let me like students might have this question that what kind of work and what kind of, what part of the project they can get involved in, right. Yeah. So, currently, because we have initiated the computational part, students might think that, oh, I have no background in AI. For example, I don't know how to program and these kind of things I want to, elaborate on that a little bit. 00;19;39;13 - 00;20;01;12 Morteza Rasoulianboroujeni  You don't need to have a background in AI or how to build a model or code. We have collaborators for that. So we collaborate a lot with computer scientists from, School of Engineering, both at Etsu and other universities. Well, one, our collaborators are in University of South and California, and they've been very helpful with developing these models. 00;20;01;14 - 00;20;29;25 Morteza Rasoulianboroujeni  What we need to feed, to their models that they're developing is data. So what the students do currently, for example, as, as, part of the research elective course and the students. So journey is like we collect literally like data from literature. And we dig into different papers and articles published. We learn about the formulation, how they have formulated these lipid nanoparticles, for example, what they have measured. 00;20;29;25 - 00;20;57;18 Morteza Rasoulianboroujeni  We record all the details and it is called dataset curation. All the AI models that you see out there, they have this process like ChatGPT, all these language models, they have a backbone, like they need training data, they need to be trained on something. And that data sets is a very critical part of it. Actually. People may think that the model itself is the most critical, but many people may release the model. 00;20;57;18 - 00;21;17;27 Morteza Rasoulianboroujeni  But they may not release the data set that the training data set is very valuable in, kind of helping training an AI model. So one thing that they can get involved in, even before we have our lab established and vet lab work, is getting involved in building these data sets, and we're actively working on that with the students. 00;21;17;27 - 00;21;42;11 Morteza Rasoulianboroujeni  I see it very, attractive for students because first of all, they can have flexibility. They can work on their computers any time at home. They don't need to be in the lab at this very specific time, which is a problem for, professional degree students. And, you know, especially if you're working with sales animals and these kind of thing, it's not like I'm busy right now. 00;21;42;11 - 00;22;11;22 Morteza Rasoulianboroujeni  I have a class like you have to take care of it, right? So you cannot postpone kind of feeding animals in animal facility or injection to couple days later. The whole experiment is going to be impacted by that. So but this one is like, oh, I can be flexible. And when I do the work, that's one thing. And the second thing is that as they dig into these papers to extract the data, they read it and they learn a lot. 00;22;11;22 - 00;22;38;27 Morteza Rasoulianboroujeni  So after participating in this project for putting together this data set, they have already read 100 papers, which is like graduate students and postdocs in that field might not have that knowledge. Right, right. So they develop a solid background in that field, which will help them a lot to understand and also decide whether they want to follow that same career path in their. 00;22;39;00 - 00;22;43;13 Michele Williams That sounds really exciting and like very, very important work. 00;22;43;15 - 00;22;44;26 Stephen Woodward Thank you. Yeah. For a groundbreaking. 00;22;45;03 - 00;22;45;21 Michele Williams Yeah. 00;22;45;24 - 00;22;48;25 Stephen Woodward So thank you so much for joining us today. We really appreciate. 00;22;48;25 - 00;22;50;00 Morteza Rasoulianboroujeni  It. Yeah it was. 00;22;50;02 - 00;22;51;06 Michele Williams It was great having you. Yeah. 00;22;51;06 - 00;22;53;00 Morteza Rasoulianboroujeni  Same same. Thank you so much. 00;22;53;02 - 00;23;09;17 Stephen Woodward Thanks for listening to White Coat Radio. If you haven't already, be sure to subscribe and leave this review to learn more about ETSU Bill Gatton College of Pharmacy, visit us at ETSU dot edu slash pharmacy or follow us on social media @ETSUpharmacy. We'll see you next time.  

In this episode of The Why Project, host Drithi Das speaks with Zoya Tripathi, a Pharmaceutical Sciences student at the University of British Columbia, about how a Social Action Project (SAP) transformed the way she thinks about learning, purpose, and her future.What began as an idea to develop affordable self-diagnostic vitamin D deficiency kits evolved into a journey of real-world problem-solving, collaboration with industry leaders, and discovering the confidence to turn ideas into action.Zoya reflects on the lessons she learned beyond textbooks—communication, networking, empathy, resilience, and the courage to seek feedback. She also shares how experiential learning helped her make informed career decisions and why meaningful experiences often leave a deeper impact than academic achievements alone.Whether you're a student, parent, or educator, this conversation is a reminder that education isn't just about acquiring knowledge—it's about discovering who you are and the difference you can make.Guest: Zoya Tripathi Host: Drithi Das Sound: Maher R.Producer: Archita Puranik

Every formulation decision made early in development carries downstream implications for stability, manufacturing, scalability, and analytical strategy. As therapies become more complex and development timelines compress, getting formulation right from the start has never mattered more. In this episode of Life Science Solutions, host Chris Adkins sits down with Kymanox experts Ryan Doxey, VP of Technical Services, and Matt Owen, PhD Associate Director of CMC and Pharmaceutical Sciences. Together, they introduce the newly announced Kymanox Formulation Lab and discuss why having dedicated wet lab space is essential for true IND-enabling formulation development.While Contract Development and Manufacturing Organizations (CDMOs) are built for throughput and execution, they are typically not staffed or equipped to troubleshoot complex scientific issues. This episode explores how applying a "science driving success" approach early on bridges that gap and ensures that your clinical manufacturing timelines stay on track.Topics Include:The CDMO Bottleneck: Why contract manufacturers lack the agility to spend adequate time developing formulations, and how unsolved early issues cause costly delays in Phase 1 and Phase 2 clinical manufacturing.Quality by Design (QbD): Why developing a product merely to meet a Certificate of Analysis (CFA) is insufficient, and the importance of truly understanding your design space to inherently ensure a quality product.Real-World Case Studies: How unknown peaks during forced degradation/leachable studies can derail timelines, and why understanding complex interactions like heat-catalyzed oxidation is crucial before scaling up.Advanced Characterization: Why CDMOs often skip critical tests like permeation and mucus adhesion studies, and how using tools like nasal cast models ensures an intranasal product has adequate residence time and efficacy.Future Trends: The push for biologics and the resurgence of spray-dried formulations to improve global storage conditions, especially as standard injection vehicles struggle to handle the viscosity of high-concentration antibodies.Taking a thoughtful, science-driven approach to early formulation can help reduce risk and avoid costly development delays.

In this episode, Dr. Jan D. Hirsch, Founding Dean of the University of California, Irvine School of Pharmacy & Pharmaceutical Sciences & Professor of Clinical Pharmacy, discusses how AI, precision medicine, and interdisciplinary education are shaping the future of pharmacy while preparing the next generation of healthcare leaders to improve patient outcomes.

In this episode, Dr. Jan D. Hirsch, Founding Dean of the University of California, Irvine School of Pharmacy & Pharmaceutical Sciences & Professor of Clinical Pharmacy, discusses how AI, precision medicine, and interdisciplinary education are shaping the future of pharmacy while preparing the next generation of healthcare leaders to improve patient outcomes.

In Episode 3 of our AI in Antibodies mini-series, we speak to Peter Tessier, the Albert M. Mattocks Professor of Pharmaceutical Sciences and Chemical Engineering at the University of Michigan, about his groundbreaking work in the application of machine learning to predict and improve the formulation and delivery of therapeutic antibodies. Subcutaneous delivery of antibody therapeutics offers patients the convenience of at-home administration, but high-concentration formulations create viscosity challenges that limit practical delivery. Here, Peter explains how his team developed machine learning models that predict antibody viscosity and self-association, reveals surprising discoveries about formulation properties and shares practical guidance for antibody developers.Contents:[01:00] Pros and cons of subcutaneous delivery [03:30] Favorable antibody characteristics for subcutaneous delivery[05:20] Predicting viscosity[10:10] Zooming in on self-association for antibodies[15:10] Predicting sell-association based on antibody characteristics and external factors and formulation properties.[22:00] Advice for antibody therapeutics developers[24:45] Closing remarks and final requests Hosted on Acast. See acast.com/privacy for more information.

At this year's PEGS Boston, industry experts gathered on a panel to explore how AI and machine learning are deployed in biologics R&D today. Moderated by Peter M. Tessier, Ph.D., Albert M. Mattocks professor of pharmaceutical sciences and chemical engineering at University of Michigan, the panel consisted of Andrew Buchanan, Ph.D., head of discovery at a stealth-mode biotech company; Norbert Furtmann, Ph.D., head of biologics AI and design of large molecules research at Sanofi; Konrad S. Krawczyk, Ph.D., founder and CSO at NaturalAntibody SA; Andrew C.R. Martin, Ph.D., emeritus professor of bioinformatics and computational biology at University College London; Melody Shahsavarian, Ph.D., senior director of data strategy and digital transformation of biotherapeutics discovery research at Eli Lilly & Company; and Bernhardt L. Trout, Ph.D., professor of chemical engineering at Massachusetts Institute of Technology.  Links from this episode:  Pharmaceutical Sciences & Chemical Engineering, University of Michigan University of Michigan Sanofi NaturalAntibody SA Bioinformatics, UCL Biosciences Computational Biology, UCL University College London   Eli Lilly & Company 

BUFFALO, NY – June 8, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on June 3, 2026, titled “The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation.” The study was led by first author Kweku Ofosu-Asante and corresponding author Nazarius S. Lamango from the Florida A&M University College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health in Tallahassee, Florida. Pancreatic ductal adenocarcinoma is among the deadliest forms of cancer, due in large part to the high frequency of KRAS mutations that drive tumor growth and resistance to treatment. Although targeted therapies have recently been developed for specific KRAS mutations, many patients continue to have limited treatment options, highlighting the need for broader strategies capable of targeting multiple KRAS-driven cancers. In this study, researchers investigated a class of experimental compounds known as polyisoprenylated cysteinyl amide inhibitors (PCAIs), which were originally designed to disrupt abnormal KRAS signaling. Using pancreatic cancer cell lines carrying KRAS mutations, the team explored how these compounds affect cancer cell survival, migration, invasion, and the molecular pathways that regulate tumor growth. Full press release - https://www.oncotarget.com/news/pr/experimental-compounds-trigger-cancer-cell-death-in-kras-driven-pancreatic-cancer/ DOI - https://doi.org/10.18632/oncotarget.28879 Correspondence to - Nazarius S. Lamango - nazarius.lamango@famu.edu Abstract video - https://www.youtube.com/watch?v=asbhjME7rFQ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28879 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PCAIs, PDAC, MAPK, PI3K/AKT, KRAS To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

DRIPA appeal GUEST: Robin Junger, Lawyer at McMillan LLP $1 billion for the World Cup GUEST: Moshe Lander, Senior Economics Lecturer AT Concordia University Generic Ozempic GUEST: Brian Rodrigues, Professor in the Faculty of Pharmaceutical Sciences and Molecular and Systems Pharmacology at UBC Learn more about your ad choices. Visit megaphone.fm/adchoices

Creatine, melatonin, peptides, protein powders, green powders, probiotics, multivitamins, and much more: A pharmaceutical scientist breaks down the evidence and busts the myths. Dr. Mahtab Jafari is a Professor of Pharmaceutical Sciences and Ecology & Evolutionary Biology at the University of California, Irvine, and the Founding Director of the UC Irvine Center for Healthspan Sciences. She is the author of the award-winning book, The Truth About Dietary Supplements: An Evidence- Based Guide to a Safer Medicine Cabinet.   In this episode we talk about: Product quality, safety, and regulation The most important thing to do before starting dietary supplements Vitamins B, C, and D (and the multivitamin debate) The research on amino acids and peptides The truth behind sleep supplements The efficacy of herbs, botanicals, and green powders Heavy metal risk factors Supplements for brain health and muscle growth Probiotics and gut health Get the 10% with Dan Harris app here Sign up for Dan's free newsletter here Follow Dan on social: Instagram, TikTok Subscribe to our YouTube Channel Join Dan and Emmy Award-winning journalist Allison Gilbert at 92NY on May 17th for a live conversation about how mindfulness can deepen connection and combat loneliness, available in person and via streaming. Register here. Join Dan, Sebene Selassie, and Jeff Warren for Meditation Party, a 3-day immersive retreat at the Omega Institute in Rhinebeck, NY, October 16–18. Grab your in-person spot here, or sign up to livestream here! This episode is sponsored by:  BetterHelp: Find support and have someone with you in therapy. Sign up and get 10% off at BetterHelp.com/happier. Fast Growing Trees: Get 20% off your first purchase when using the code HAPPIER at checkout, fastgrowingtrees.com. Warby Parker: Buy one prescription pair and get 20% off any additional prescription pairs at warbyparker.com/happier.  To advertise on the show, contact sales@advertisecast.com or visit https://advertising.libsyn.com/10HappierwithDanHarris

South Africa’s medicines regulator is under pressure over plans to phase out a common cold and flu ingredient found in everyday remedies. But does phenylephrine actually work — or have consumers been paying for a placebo? Lester Kiewit speaks to Dr Andy Gray, senior Lecturer Division of Pharmacology, Discipline of Pharmaceutical Sciences at UKZN about the science, the pushback from industry, and what it means for your next trip to the pharmacy. Good Morning Cape Town with Lester Kiewit is a podcast of the CapeTalk breakfast show. This programme is your authentic Cape Town wake-up call. Good Morning Cape Town with Lester Kiewit is informative, enlightening and accessible. The team’s ability to spot & share relevant and unusual stories make the programme inclusive and thought-provoking. Don’t miss the popular World View feature at 7:45am daily. Listen out for #LesterInYourLounge which is an outside broadcast – from the home of a listener in a different part of Cape Town - on the first Wednesday of every month. This show introduces you to interesting Capetonians as well as their favourite communities, habits, local personalities and neighbourhood news. Thank you for listening to a podcast from Good Morning Cape Town with Lester Kiewit. Listen live on Primedia+ weekdays between 06:00 and 09:00 (SA Time) to Good Morning CapeTalk with Lester Kiewit broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/xGkqLbT or find all the catch-up podcasts here https://buff.ly/f9Eeb7i Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalkSee omnystudio.com/listener for privacy information.

Welcome to the Mad in America podcast, my name is James. Today, we are discussing the experiences of people who have attempted to stop taking psychiatric drugs. These experiences are captured in a survey undertaken by the School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland. Joining me to talk about this work are Cathal Cadogan and Agnes Higgins, both from Trinity College. Cathal is an Associate Professor in Practice of Pharmacy at Trinity College. His research focuses on developing supports to help people make informed decisions about starting and stopping psychiatric medication. He was recently involved in a priority setting partnership to identify priorities for future research on reducing and discontinuing psychiatric medicines. Agnes is a nurse, researcher and academic who has recently retired as a professor in mental health at the School of Nursing and Midwifery at Trinity College. She is a former Chairperson of the Board of Mental Health Reform, Ireland's leading service user organization, campaigning for improvements in mental health services. She is also currently a board member of Kyrie Farm, an innovative initiative combining the benefits of nature, meaningful participation, community and therapy to support mental health recovery. Their work is part of a wider examination of priorities for future research on reducing and stopping psychiatric medication, and we'll talk about this as well as the findings of their survey. We'll also talk about the role that pharmacists could potentially play when people are considering stopping their psychiatric drugs. *** Thank you for being with us to listen to the podcast and read our articles this year. MIA is funded entirely by reader donations. If you value MIA, please help us continue to survive and grow. https://www.madinamerica.com/donate/ To find the Mad in America podcast on your preferred podcast player, click here: https://pod.link/1212789850 © Mad in America 2026. Produced by James Moore https://www.jmaudio.org

 In this episode of the PQS Quality Corner Show, hosts Kerri Musselman and Emily Endres celebrate Heart Health Month by exploring the critical link between community pharmacy, maternal health, and cardiovascular wellness. Their guest, Andrea Brookhart (Director of Population Health and Wellness at Kroger), shares her insights as both a clinical leader and a mother of twins.This episode touches on the Pharmacist as an accessible ally, the "Silent Killer" and prevention, gender differences in cardiac care, the "Mom Factor,” and self-care.Dr. Andrea Brookhart is a community pharmacist who is passionate about helping people live healthier lives.  In her role, she develops and implements Kroger Health's strategy for achieving population health via value-based care.  She believes community-based providers are uniquely poised to improve healthcare quality and decrease cost by delivering preventive healthcare and improving medication use.Dr. Brookhart is a graduate of the University of Toledo College of Pharmacy & Pharmaceutical Sciences and of Virginia Commonwealth University's Community-based Pharmacy Residency Program a Board Certified Ambulatory Care Pharmacist. 

TWIRx – January 30 | Special Guest: Marc Essensa, CEO of IPC On this episode of This Week in Pharmacy, we welcome Marc Essensa, President and CEO of the Independent Pharmacy Cooperative (IPC), to discuss timely strategies and resources helping independent pharmacies strengthen their businesses in today's challenging environment. Building Your Independent Pharmacy Business Marc shares insights on navigating reimbursement pressure, improving margins, and leveraging IPC's purchasing power, data, and strategic tools to support long-term sustainability. The Payment Card Settlement: A Practical Guide We break down IPC's guidance on the Payment Card Interchange Fee Settlement, which may allow pharmacies that accepted Visa or Mastercard between 2004–2019 to recover funds. Marc explains eligibility, next steps, and how recovered dollars can support cash flow, staffing, technology, or inventory investments. IPC Member Support Services The conversation highlights IPC's expanded member support offerings, including business consulting, strategic partnerships, wholesale access, and operational resources designed to help independents stay competitive. Legislative & Advocacy Updates Marc also provides updates on IPC's advocacy efforts at both the state and federal levels, focused on protecting independent pharmacy interests and addressing ongoing policy and reimbursement challenges.

In this month's podcast episode, The Standards, hosts Neil Skolnik, MD, and Sara Wettergreen, PharmD, BCACP, BC-ADM, explain the Standards of Care in Diabetes from the American Diabetes Association® in clear, plain terms. This conversation is designed to help you better understand the guidance that shapes diabetes and obesity care. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to "follow" Diabetes Day by Day!   Additional resources: Access the Standards of Care in Diabetes—2026 Access sections 1-3 of the Standards of Care in Overweight and Obesity Access Your Rights and Care Standards: A Guide for People with Type 2 Diabetes          

In this episode, our guest is Mary V. Relling, Pharm.D. Emerita Member, Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN. Dr. Relling earned her undergraduate B.S. degree from the University of Arizona College of Pharmacy and her doctoral degree from the University of Utah College of Pharmacy. She completed post-doctoral fellowships with Dr. William Evans at St. Jude and with Dr. Urs Meyer at University of Basel. She joined St. Jude as a faculty member in 1988, and was chair ofthe Department of Pharmaceutical Sciences from 2003-2020. She was also a professor at the University of Tennessee in the Colleges of Medicine and Pharmacy. Her primary interests are in the treatment and pharmacogenetics of childhood leukemia and in the clinical implementation of pharmacogenetic testing in medicine. Dr. Relling is co-founder of CPIC, the Clinical Pharmacogenetics Implementation Consortium. She has published over 450 original scientific manuscripts. She was elected to the Institute of Medicine (National Academy of Medicine) in 2009.Topics to discuss:Foundations & Career JourneyYou've had an extraordinary career at St. Jude since joining in 1988. What first drew you to pediatric pharmacology and pharmacogenetics?Your work has helped shape how we treat childhood leukemia. What do you see as the most transformative advancements in this space over your career?Pharmacogenetics & CPICYou co-founded the Clinical Pharmacogenetics Implementation Consortium (CPIC). What was the impetus behind its creation, and how has its mission evolved?What do you see as the biggest barriers to widespread clinical implementation of pharmacogenetic testing today?How do you respond to skepticism about the clinical utility of pharmacogenetic testing in everyday medical practice?Which pharmacogenetic guidelines do you believe have had the most significant clinical impact so far—and why?What advice do you have for institutions that want to start implementing pharmacogenetic testing but don't know where to begin?Implementation in Clinical SettingsAt St. Jude, you helped lead efforts to integrate pharmacogenetic testing into clinical care. What lessons did you learn about operationalizing this work in real-world settings?How important is interdisciplinary collaboration—between pharmacists, physicians, geneticists—in making pharmacogenetic testing work in practice?Can you share an example where pharmacogenetic testing changed the course of treatment for a pediatric patient?Policy, Ethics, and Future VisionWhat policy or regulatory changes would help accelerate the clinical adoption of pharmacogenetic testing?As someone who has contributed extensively to the science, how do you think we should balance data privacy with the need for clinical data sharing in genomics?What are you most excited about in the future of pharmacogenetics? Are there particular therapeutic areas or technologies that you think will drive the next wave of innovation?Legacy & AdviceYou've mentored many rising leaders in the field. What qualities do you think are most important for the next generation of pharmacogenomics researchers and clinicians?With over 450 publications and a career that has changed pediatric pharmacology, what legacy do you hope your work leaves behind?Guest: Mary V. Relling, Pharm.D. Emerita Member, Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research HospitalHost: Hillary Blackburn, PharmD, MBAwww.hillaryblackburn.comhttps://www.linkedin.com/in/hillary-blackburn-67a92421/  ★ Support this podcast on Patreon ★

Guest: Dr Colm McKeever, Assistant Lecturer and Researcher in Analytical Chemistry, Department of Pharmaceutical Sciences and Biotechnology, at TUS

In this episode of Diabetes Day by Day, Drs. Neil Skolnik and Sara Wettergreen talk with Dr. Akturk about the potential health risks associated with cannabis use for people living with diabetes. Cannabis use can affect blood glucose management, heart health, and even how someone manages their medications.  Understanding the risks of cannabis use is an important part of managing diabetes safely. Staying informed and having open conversations with your health care team are the best ways to protect your health. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Halis Kaan Akturk, MD, Associate Professor of Medicine and Pediatrics, Barbara Davis Center for Diabetes, University of Colorado, Aurora, CO Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to "follow" Diabetes Day by Day!

Artificial intelligence, or, AI is on everyone's minds, and we're all still figuring out how to trust it, teach it, and use it responsibly. Today we take a deep dive into how AI is affecting the education of current and future pharmacy students. With us is Jennifer Trujillo, associate Dean for education and professor in the Department of Clinical Pharmacy at the Skaggs School of Pharmacy and Pharmaceutical Sciences on the University of Colorado Anschutz Medical Campus in Aurora, Colorado, and Logan Tinsen, the clinical pharmacy manager and residency program director at Benefis Hospital in Great Falls, Montana.   Guest speakers:  Jennifer Trujillo, PharmD, BCPS, CDCES, BC-ADM Associate Dean for Education Professor, Department of Clinical Pharmacy Skaggs School of Pharmacy and Pharmaceutical Sciences University of Colorado Anschutz Medical Campus Logan Tinsen, PharmD, FMPA Clinical Pharmacy Manager and Residency Program Director Benefits Hospitals   Host:   Kerry Schwarz, PharmD, MPH   Senior Clinical Manager, Evidence-Based Medicine and Outcomes  Center for Pharmacy Practice Excellence (CPPE)   Show Notes:  [01:02-03:45] Challenges with AI in pharmacy education [03:46-05:59] The AI adoption spectrum: Pitfalls of extremes between full and limited adoption [06:00-11:18] Approaches to pharmacy education in the early stages of AI [11:19-14:55] Guardrails and safeguards [14:56-16:29] Key takeaways about AI right now for pharmacy educators   VerifiedRx Listener Feedback Survey: We would love to hear from you - Please click here   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed

Guests:Dr Colm McKeever, Assistant Lecturer and Researcher in Analytical Chemistry, Department of Pharmaceutical Sciences and Biotechnology, at TUSDr Shelley Brady, DCUDr Laura Hayes, DIAS

In this episode of Diabetes Day by Day, Drs. Neil Skolnik and Sara Wettergreen talk with Aaron Sutton, LCSW, BCD, CAADC, and Casey Coffman about decision fatigue—what it means and ways to cope, especially as the holiday season approaches. Living with diabetes means making countless decisions every day—from meal choices to medication timing. Over time, this can lead to decision fatigue, impacting both your mental health and diabetes management. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Aaron Sutton, LCSW, BCD, CAADC, Director of the Sutton Institute for Psychotherapy Casey Coffman, American Diabetes Association® volunteer and a person living with type 1 diabetes Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to "follow" Diabetes Day by Day!

Join Drs. Neil Skolnik and Sara Wettergreen as they answer one of the most common questions people living with diabetes have: “What diabetes medication is best for me?”   In this episode, they'll explore how choosing the right medication depends on your individual health, lifestyle, and goals. Discover practical tips to better help you work with your care team to make informed decisions and find the best treatment plan for you.   Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to “follow” Diabetes Day by Day!   Diabetes Medications: Biguanides Brand: Glucophage, Fortamet, Glumetza Generic: Metformin, Metformin XR Sulfonylureas (Second Generation) Brand: Glucotrol, Amaryl, Diaβeta, Glynase Generic: Glipizide, Glipizide XL, Glimepiride, Glyburide Thiazolidinediones (TZDs) Brand: Actos, Avandia Generic: Pioglitazone, Rosiglitazone (no longer available) DPP-4 Inhibitors Brand: Januvia, Onglyza, Tradjenta, Nesina Generic: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin SGLT2 Inhibitors Brand: Invokana, Farxiga, Jardiance, Steglatro, Brenzavvy Generic: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin, Bexagliflozin GLP-1 Receptor Agonists Brand: Victoza, Trulicity, Ozempic, Rybelsus, Mounjaro (dual GIP/GLP-1) Generic: Liraglutide, Dulaglutide, Semaglutide, Tirzepatide Insulins (selected examples) Brand: Humalog, NovoLog, Apidra, Lantus, Basaglar, Levemir, Tresiba, Humulin N, Novolin N, Humulin R, Novolin R Generic: Insulin lispro, Insulin aspart, Insulin glulisine, Insulin glargine, Insulin detemir, Insulin degludec, NPH insulin, Regular insulin

Send us a textDrug-resistant germs are hidden killers in more than one way. Not only are the microbes invisible to the human eye, in many places, they're invisible because people simply are not looking for them systematically.Doctors often do not know what infections their patients have and treat them based on best guesses, which allows for ineffective treatments and exacerbates drug resistance. Policymakers don't know which infections are most common among populations and cannot make informed decisions about needed treatments or vaccines.This is a major problem across Africa and a new report shows just how complex the problem is.The Mapping AMR and Antimicrobial use Partnership (MAAP), which included the One Health Trust as well as the African Society for Laboratory Medicine; Africa CDC; the East, Central, and Southern Africa Health Community; Innovative Support to Emergencies, Diseases, and Disasters, a nonprofit focused on technology and communication;  the clinical research group IQVIA; and the West African Health Organization, collected data from laboratories from 14 countries in Africa (Burkina Faso, Cameroon, Gabon, Ghana, Kenya, Eswatini, Malawi, Nigeria, Senegal, Sierra Leone, Tanzania, Uganda, Zambia, and Zimbabwe). “The study revealed significant gaps in bacteriology testing capacities,” the group, whose work was paid for by the UK government's Fleming Fund, wrote in PLoS Medicine.It's the biggest survey yet of testing for antimicrobial resistance – AMR or drug resistance – in Africa.Among the gaps: too little testing overall, a lack of laboratory capacities, and poor coordination and analysis of records. Many records were kept only on paper, which made them almost impossible to access.None of this surprises Dr. Sabiha Essack, South African Research Chair in Antibiotic Resistance and One Health and Professor in Pharmaceutical Sciences at the University of KwaZulu-Natal. In an ideal world, she says, a doctor, nurse or other professional should see a patient, test them to see what specific microbe is causing an infection, check to see which drugs will successfully fight that germ, and then treat the patient accordingly.Cheap point-of-care tests should be available everywhere and the results of those tests should be entered into systems that officials can use to make policy decisions, she says. Listen as she tells One World, One Health host Maggie Fox other ways to improve our knowledge about the drug-resistant infections that lurk out there. Want to know more? You can find One World, One Health episodes on drug-resistant infections in cancer patients; superbugs and microplastics; the personal toll of antibiotic resistance; one woman's antibiotic resistance nightmare; how to prevent drug resistance, and more.

Celebrate the American Diabetes Association®'s (ADA) 85th anniversary with Drs. Neil Skolnik and Sara Wettergreen, joined by Dr. Marlon Pragnell, Charlene Wallace, and Stacey Krawczyk. Together, they'll reflect on the ADA's legacy of groundbreaking research and how it continues to shape the programs and resources available today. The conversation will also highlight practical tools—from nutrition guidance to the National Diabetes Prevention Program—to support you and your loved ones in managing or preventing diabetes. Because it all matters. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Marlon Pragnell, PhD, Vice President of Research and Science at the ADA Charlene Wallace, MBA, Vice President of Diabetes Prevention at the ADA Stacey Krawczyk, MS, RD, Director of Nutrition and Wellness at the ADA Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to “follow” Diabetes Day by Day!   Additional resources: Research Impact   Learn More About the National Diabetes Prevention Program    Eating for Diabetes Management   Diabetes Food Hub   More on the ADA's 85th Anniversary

Opioid misuse and overdoses are a serious public health crisis across Washington state and nationwide. From 2019 to 2021, the annual number of opioid drug overdose deaths in the state nearly doubled. About 55 people in America die each day from an overdose of prescribed or illicit opioids, including fentanyl and heroin.It's crucial to get real information and education on opioid use to communities. Washington State University faculty and staff, including assistant professor Nicole Rodin at the College of Pharmacy and Pharmaceutical Sciences, have teamed up with colleagues across Washington to get accurate and useful facts out to people and try to prevent overdoses. They've focused on rural communities hit hard by opioid use, often with limited medical facilities and support.Rodin talks with Washington State Magazine editor Larry Clark about the scope of the opioid epidemic, effective education, reducing stigma, and how we can all lend our support.There's a need to treat substance use disorders as health care, Rodin says. “It is a disorder. It is a medical condition, and we have yet to treat it that way as a society.”Read more about WSU efforts on curbing substance use and addiction in the Spring 2024 issue of Washington State Magazine.Other resources:Rural Opioid Technical Assistance Collaborative (Northwest Region 10)Opioid Overdose Prevention, Recognition, and Response (Washington State Department of Health)How to talk about substance use (Washington State Magazine, Spring 2024)WSU PEAR—Program of Excellence in Addictions ResearchWSU APPL—Analytics and PsychoPharmacology LaboratorySupport the show______________________________________________________________________________Want more great WSU stories? Follow Washington State Magazine: LinkedIn @Washington-State-Magazine Bluesky @wastatemagazine.bsky.social X (formerly Twitter) @wsmagazine Facebook @WashingtonStateMagazine Instagram @WashingtonStateMagazine YouTube @WashingtonStateMagazine Email newsletter How do you like the magazine podcast? What WSU stories do you want to hear? Let us know. Give to the magazine

BUFFALO, NY - August 13, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on July 29, 2025, titled “PCAIs stimulate MAPK, PI3K/AKT pathways and ROS-Mediated apoptosis in aromatase inhibitor-resistant breast cancer cells while disrupting actin filaments and focal adhesion.” In this study, led by first author Jassy Mary S. Lazarte and corresponding author Nazarius S. Lamango from Florida A&M University College of Pharmacy and Pharmaceutical Sciences, researchers investigated a new class of compounds called polyisoprenylated cysteinyl amide inhibitors (PCAIs) as a potential treatment for aromatase inhibitor (AI) therapy resistant breast cancer. Aromatase inhibitors are a common treatment for estrogen receptor-positive (ER+) breast cancer, but many patients eventually develop resistance, leaving fewer therapeutic options. The study focused on a PCAI compound called NSL-YHJ-2-27, which was tested in long-term letrozole-treated breast cancer cells (LTLT-Ca), an experimental model of AI therapy resistance. NSL-YHJ-2-27 activated two major signaling pathways, MAPK and PI3K/AKT. Although these pathways typically support cancer cell survival, their overstimulation by PCAIs led to increased oxidative stress, damaging the cells and inducing cell death by apoptosis. The compound also reduced levels of RAC1 and CDC42, proteins involved in maintaining cell shape and movement. These alterations resulted in cytoskeletal disruption and reduced structural integrity, making the cancer cells more vulnerable and less capable of spreading. Importantly, the effects of NSL-YHJ-2-27 persisted after the compound was removed, suggesting long-term control over AI resistant cancer cells may be possible. “PCAIs inhibited cell proliferation and colony formation by 95% and 74%, respectively, increased active caspase 7 and BAX 1.5-fold and 56%, respectively. NSL-YHJ-2-27 (10 μM) induced LTLT-Ca spheroid degeneration by 61%.” As a new class of targeted molecules, PCAIs represent an innovative approach distinct from traditional endocrine therapies. Their ability to affect multiple cellular mechanisms simultaneously makes them promising candidates for future drug development. Overall, this study presents a promising new approach for treating AI therapy-resistant breast cancer. By targeting cellular pathways that support survival and mobility, PCAIs like NSL-YHJ-2-27 could provide a novel strategy to manage advanced or resistant forms of the disease. Further research, including in vivo studies and clinical trials, will be essential to confirm these findings and evaluate their therapeutic potential. DOI - https://doi.org/10.18632/oncotarget.28759 Correspondence to - Nazarius S. Lamango - nazarius.lamango@famu.edu Video short - https://www.youtube.com/watch?v=8xQEilloO9Q Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28759 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PCAIs, ROS, MAPK, PI3K/AKT, LTLT-Ca cells To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

In this episode, we review how genomics is being used to fight against antimicrobial resistance (AMR). From outbreak tracking to detecting resistance genes, genomic tools are transforming how we understand, diagnose, and manage infectious threats. About our Guest: Professor Sabiha Essack is a seasoned researcher and a former Wellcome Trust Research Fellow who completed research towards her PhD in Pharmaceutical Microbiology at St Bartholomew's and the Royal London School of Medicine and Dentistry in the United Kingdom. She currently serves as the South African Research Chair (SARChI) in Antibiotic Resistance and One Health and a Professor in Pharmaceutical Sciences at the University of KwaZulu-Natal (UKZN). View her inspiring and versatile biography HERE! WE'D LOVE YOUR FEEDBACK ON THIS EPISODE – Visit the Microbe Mail website to sign up for updates Follow on:Instagram: Microbe_MailX/Twitter: @microbemailFacebook: MicrobeMailTiktok: @microbe.mailWatch this episode on our new YouTube channel: Microbe MailE-mail us: mail.microbe@gmail.com

Hey team! Our guest today is Dr. Otito Iwuchukwu, who is here to talk about the emotional and psychological aspects of belonging and how it impacts our day-to-day lives. Dr. Iwuchukwu has a Master of Arts in Organizational Psychology from the College of Psychology and Counseling, a Ph.D. in Pharmaceutical Sciences, with a specialization in Drug Metabolism and Pharmacokinetics, from Temple University, and is currently an Associate Professor at Fairleigh Dickinson University. Her scholarly contributions appear in a range of peer-reviewed and indexed publications and have been presented at numerous research meetings and symposia across the world. Additionally, Dr. Iwuchukwu has recently written The Belonging Paradox, a book that presents a new way to understand belonging as an adaptive journey rather than a static destination. In this episode, we talk about why belonging is a dynamic, ongoing process, not a fixed state, and how we can create more inclusive environments for ourselves and others. We'll also discuss how masking impacts our sense of belonging, the role boundaries play in maintaining our authenticity, and the importance of giving ourselves and others grace. If you've ever struggled with finding your place, especially in social settings or work environments, you'll find practical tools in this conversation for navigating those tough moments. The Belonging Paradox - https://www.otitoiwuchukwu.com/new-book/ Dr. Otito Iwuchukwu on LinkedIn - https://www.linkedin.com/in/otitoiwuchukwu/ If you'd life to follow along on the show notes page you can find that at https://HackingYourADHD.com/232 https://tinyurl.com/y835cnrk - YouTube https://www.patreon.com/HackingYourADHD - Patreon This Episode's Top Tips 1. Belonging isn't a fixed state, but an ongoing process that changes with both your internal state and the external environment. Recognizing this can help you manage expectations and frustrations when your sense of belonging fluctuates. 2. Recognize that you don't have to belong to every group, and not all groups are meant for a deep, personal connection. Don't force yourself to belong in every situation; if a group or environment doesn't feel right, it's okay to step back. 3. You don't have to be liked by everyone. Instead, it's important for us to focus on finding spaces where we can truly belong. It's about finding authentic connections, not chasing superficial acceptance.

Join Drs. Neil Skolnik and Sara Wettergreen as they discuss key takeaways from the ADA's 85th Scientific Sessions in Chicago, highlighting advancements in diabetes and obesity care. With guests, Drs. Osagie Ebekozien and Marlon Pragnell, they'll explore how these advancements can positively impact you and your loved ones.   Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Osagie Ebekozien, MD, MPH, CPHQ, Chief Quality Officer at the ADA  Marlon Pragnell, PhD, Vice President of Research and Science at the ADA Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to “follow” Diabetes Day by Day!   Additional resources: Patient Standards of Care 2025 Need information on diabetes, ADA programs, or upcoming events? The ADA's Center for Information is here to help. Contact them directly at 1-800-DIABETES (1-800-342-2383) or email AskADA@diabetes.org for personalized guidance and support.

Dr. Renee Coffman is president and co-founder of the Nevada College of Pharmacy, now Roseman University of Health Sciences. She previously served as the University's Executive Vice President for Quality Assurance and Intercampus Consistency and the Dean of its College of Pharmacy. Before establishing Roseman University, Dr. Coffman became a founding member of the faculty at Western University of Health Sciences, where she also held the position of Facilitative Officer for Student Services. While at Western, Dr. Coffman and four colleagues received Honorable Mention for the AACP Innovations in Teaching Awards. A licensed pharmacist in the state of Nevada, Dr. Coffman earned a Pharmacy degree from OhioNorthern University in 1987 and, following graduation, worked as a pharmacist in her hometown of Bucyrus, Ohio and in Piqua, Ohio. In 1995, Dr. Coffman earned a doctoral degree in Industrial and Physical Pharmacy from Purdue University, where she received the Kienle Award for Excellence in Teaching, the Jenkins-Knevel Award for Outstanding Graduate Research, and was awarded an AAPE-AFPE Association Fellowship in Pharmaceutical Sciences.Dr. Coffman is a member of the American Association of Colleges of Pharmacy, American Pharmaceutical Association, American Association of Pharmaceutical Scientists, the American Society of Health System Pharmacists, and the International Federation of Pharmacy, as well as Phi Kappa Phi and Rho Chi Honor Societies and the Phi Lambda Sigma Pharmacy Leadership Society. Dr. Coffman has worked to support pharmacy, education, and improved health care through herwork with the Southern Nevada Medical Industry Coalition, iDO (Improving Diabetes and Obesity inSouthern Nevada), the Nevada State Board of Pharmacy Medication Error Discussion Group, and theNevada State Board of Pharmacy Committee on Standards for Approval of Pharmacy Technician Training Programs. Additionally, Dr. Coffman was instrumental in successful legislative efforts permitting pharmacists to perform finger-stick blood glucose testing. In recognition of her community service in Southern Nevada, in 2008, she received the “Who's Who in Healthcare” Award and the “Women of Distinction” Award, both sponsored by In Business Las Vegas, now VEGAS INC. In 2017, the publication recognized Dr. Coffman as one of 12 “Women to Watch” in business. In 2012, she was named a “Distinguished Alumnus” by Ohio Northern University and in 2021 was named a “Distinguished Alumnus” by Purdue University.

 Tune in to this episode featuring Drs. Neil Skolnik and Sara Wettergreen as they explore the power of storytelling and how it brings us together. Special guests Marlee Seibold and Dr. Saige Kiedinger shared their personal experiences with type 1 diabetes, including— challenges, triumphs, and the everyday moments that have shaped their journeys. We hope that by listening to their stories, you'll gain a deeper understanding of the power of storytelling and feel inspired to share your own journey. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Marlee Seibold: Storytelling Communications Manager at the ADA and a person living with type 1 diabetes.   Dr. Saige Kiedinger: A recent pharmacy school graduate transitioning to residency training, also living with type 1 diabetes.   Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to “follow” Diabetes Day by Day!   Want to share your journey with us? Share it now here.

Get ready for Part One of a special two-part episode of A SkinDepth Convo!Part one dives into one of the most essential yet overlooked aspects of skincare science: Emulsions. Then, in part two, we'll explore the chemistry behind sunscreen and SPFs.Joining Metaxia and Francine is a true expert in cosmetic science, Dr. Gabriella Baki. She's an associate professor at the University of Toledo's College of Pharmacy and Pharmaceutical Sciences and the Program Director of its groundbreaking Cosmetic Science and Formulation Design major. Dr. Baki teaches both undergraduate and online master's students while leading research in topical ingredient delivery, sun protection, and the sensory experience of skincare products.Don't miss this deep-dive into the science behind the products we use every day!

June 10, 2025 | This episode of The Chain features a panel discussion from May's PEGS Boston. Moderated by Peter Tessier, Albert M. Mattocks professor of Pharmaceutical Sciences and Chemical Engineering at the University of Michigan, the panelists include Sarel Fleishman, professor of Biomolecular Sciences at the Weizmann Institute of Science; Kadina Johnston, senior specialist of Discovery Biologics at Merck & Co.; Vincent Ling, chief business officer of Morphocell Technologies; Arvind Rajpal, SVP of Xaira; and Max Vasquez, chief computing officer of Adimab. Together they discuss benchmarking AI/ML methods compared to traditional approaches, development of human-relevant training data, identifying and addressing core challenges in de novo designs, and more. Links from this episode:  PEGS Boston Conference & Expo Engineering Bispecific Antibodies University of Michigan University of Michigan Chemical Engineering Weizmann Institute of Science Scala Biodesign Merck & Co., Inc. Morphocell Technologies Bill & Melinda Gates Foundation Xaira Adimab LLC 

Join Drs. Neil Skolnik and Sara Wettergreen in this episode as they discuss the importance of emotional wellbeing in overall health. They will explore the connection between mental health and diabetes, focusing on how managing a chronic condition can impact the emotional lives of people living with diabetes and their families. Special guest Dr. Kelsey Brzezinski will also join the conversation.   Please note that this episode includes discussions of sensitive topics, we encourage you to listen with care and understand that the American Diabetes Association® is not an organization that specializes in mental health and only seeks to bring awareness to factors that coincide with a diabetes diagnosis. If you are experiencing challenges seek the support of a licensed medical or mental health professional. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Kelsey Brzezinski, PhD, Pediatric Psychologist at Lurie Children's Hospital of Chicago, Assistant Professor of Psychiatry and Behavioral Sciences at Northwestern University Feinberg School of Medicine, Chicago, IL   Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to “follow” Diabetes Day by Day!   Additional resources: If you or a loved one are experiencing a mental health crisis, please call the 988 Suicide & Crisis Lifeline. SAMHSA mental health help line, which is a no-cost, confidential, 24/7, 365-day-a-year treatment referral and information service available at 1-800-662-HELP (4357). Check out the American Diabetes Association®'s newly updated Mental Health Provider Directory to find to find therapists who specialize in supporting people living with diabetes near you.  

A new episode of Diabetes Day by Day is here! Join Drs. Neil Skolnik and Sara Wettergreen as they share tips to increase movement in honor of April being Move More Month. Since we're all about movement and exercise, we're excited to welcome special guests Adrienne Edge and David Rachal III from the American Diabetes Association®'s (ADA) Project Power program. They'll share how you can get involved and start moving to stay healthy, prevent, or better manage type 2 diabetes. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Adrienne Edge, Founder of ProFIT Family Wellness, Community Partner and Facilitator Trainer for the ADA's Project Power program   David Rachal III, Nationally Respected Leader in Medical Fitness, Wellness, and Entrepreneurial Empowerment, Community Partner and Facilitator Trainer for the ADA's Project Power program   Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to “follow” Diabetes Day by Day!   To learn more about Project Power, be sure to check out: diabetes.org/ProjectPower.

Join Drs. Neil Skolnik and Sara Wettergreen as they delve into the differences between FDA-approved medications and compounded and counterfeit medications, alongside special guests Dr. Susan Kuchera and Lisa Kessler. They will explore the factors that might influence the decision to use compounded treatments, the risks associated with these treatments, and one of our guests will share their personal experience with obesity treatment. This episode of Diabetes Day by Day is supported by Lilly. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Susan Kuchera, MD, Clinical Assistant Professor of Family and Community Medicine at the Sidney Kimmel Medical College of Thomas Jefferson University and Program Director of the Family Medicine Residency at Jefferson Health Abington   Lisa Kessler, MS, CCC-SLP, Infant-toddler Home-based Pediatric Speech-Language Pathologist   Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to “follow” Diabetes Day by Day! Learn more about the risks of buying medications online at the BeSafeRx website, the Food and Drug Administration's source for online pharmacy information. Read the American Diabetes Association®'s statement on compounded medications. 

Garth wants to know, given the skin can block water from passing through it, how do certain skin creams allege to permeate into our body? James Tytko took on the question with help from Richard Guy, Professor of Pharmaceutical Sciences at the University of Bath... Like this podcast? Please help us by supporting the Naked Scientists

With biosimilars entering the market for the treatment of osteoporosis, there is a lot healthcare providers need to know. On this episode, Dr. Alan Low, a Clinical Professor in the Faculty of Pharmaceutical Sciences at the University of British Columbia, Care Director at MedInfuse Health, Primary Care Pharmacist / Pharmacy Lead at BioPro Biologics Pharmacy Clinical and a member of Osteoporosis Canada's Scientific Advisory Council, discusses how biologics and biosimilars work, the benefits of biosimilars and how to speak to patients about these new treatment options.

A new episode of Diabetes Day by Day is here! Join Drs. Neil Skolnik and Sara Wettergreen as they dive into the world of mobile health technology and how it's shaping diabetes management. With so many apps for tracking blood glucose (blood sugar), counting carbs, and logging fitness activities, it can be tough to find the right one. In this episode, we welcome Susan Weiner, MS, RDN, CDCES, FADCES, a nutrition, health, and diabetes expert with knowledge of diabetes-related apps, and Bridget Wood, RD, LD, CDCES, who has lived with type 1 diabetes for over 15 years and has firsthand experience with apps that can assist with diabetes management. Our guests will share valuable insights on how apps can support people living with diabetes and why using them can be beneficial. This episode isn't sponsored, and we're not endorsing any specific app—just sharing examples of ones that have helped others. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Susan Weiner, MS, RDN, CDCES, FADCES — Columnist at Endocrine Today, Owner of Susan Weiner Nutrition, PLLC, and Nutrition Communicator and Media Consultant, New York City Metropolitan Area Bridget Wood, RD, LD, CDCES — Owner and Clinical Director of Bridget Wood Wellness, LLC, Reno, NV Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to “follow” Diabetes Day by Day! For additional resources, be sure to check out: FDA Alert DiabetesWise ADCES Danatech Apps and Platforms Phone apps referenced: Glucose Blood Sugar Tracker Dario Health Livongo by Teladoc Health mySugr Dexcom G7 Tidepool OMRON (for blood pressure)

Tim Ulbrich, YFP Co-Founder welcomes back David Zgarrick, PhD to share his journey into "preferment," balancing retirement, financial planning, and staying engaged through teaching and consulting. Summary In this episode, Tim Ulbrich, YFP Co-Founder, welcomes back David Zgarrick, PhD, as he shares his journey into what he calls the "preferment phase" of life. Dr. Zgarrick opens up about his transition from academia to retirement, the joy of new routines, and the power of early financial planning. He highlights the importance of staying engaged—through consulting, teaching, and meaningful activities—while keeping financial health in check. About Today's Guest David P. Zgarrick, PhD, is Professor Emeritus in the School of Pharmacy and Pharmaceutical Sciences at Northeastern University. Prior to his retirement in 2022, his positions included Associate Dean of Faculty at Northeastern's Bouvé College of Health Sciences, Acting Dean of the Northeastern's School of Pharmacy and Pharmaceutical Sciences, Chair of the Northeastern's Department of Pharmacy and Health Systems Sciences; John R. Ellis Distinguished Chair of Pharmacy Practice at Drake University College of Pharmacy and Health Sciences; and Vice-chair of Pharmacy Practice at Midwestern University Chicago College of Pharmacy. He is a licensed pharmacist, receiving a BS in Pharmacy from the University of Wisconsin - Madison and a MS and PhD in Pharmaceutical Administration from The Ohio State University. Dr. Zgarrick remains engaged in the profession of pharmacy, consulting with universities and teaching pharmacy practice management and entrepreneurship in the health sciences. His scholarly interests include pharmacy workforce research, pharmacy management and operations, pharmacy education, and development of post-graduate programs. He has published over 150 peer-reviewed manuscripts and abstracts, was co-editor of the textbook Pharmacy Management: Essentials for All Practice Settings, and authored the book Getting Started as a Pharmacy Faculty Member. He was editor-in-chief of the Journal of Pharmacy Teaching, Executive Associate Editor of Currents in Pharmacy Teaching and Learning, and is an editorial board member of Research in Social and Administrative Pharmacy. Dr. Zgarrick is active in many professional organizations, including the American Pharmacists Association (APhA) and the American Association of Colleges of Pharmacy (AACP). He served on AACP Board of Directors for twelve years in three different roles, including as Treasurer from 2016-22. Dr. Zgarrick also served on the Board of Visitors for the University of Wisconsin School of Pharmacy, the Board of Grants for the American Foundation for Pharmaceutical Education, and is a Fellow of the American Pharmacists Association. Mentioned on the Show Episode 291: Redefining Retirement with David Zgarrick, Ph.D. Facebook David Zgarrick LinkedIn David Zgarrick Instagram @davidzgarrick  YFP YouTube Channel  YFP Book a Discovery Call YFP Disclaimer Subscribe to the YFP Newsletter Tim Ulbrich on LinkedIn Tim Baker on LinkedIn YFP on Instagram YFP Facebook Group  

A new year brings a new episode of Diabetes Day by Day! Join Drs. Neil Skolnik and Sara Wettergreen as they provide an overview of the ADA's Standards of Care in Diabetes—2025 and discuss their significance. They will also explore new updates you can bring up with your primary care provider during your next visit, including recommendations for using diabetes technology, weight management strategies, including medication therapy, and the latest insights on nutrition.  Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to “follow” Diabetes Day by Day!

Daniel E. Buffington PharmD, MBA, Clinical Pharmacology Services, Inc & American Institute of Pharmaceutical Sciences discusses with Bryn Spejcher and the Every Brain Matters community how he concluded Bryn experiences cannabis-induced psychosis the night she took her friends life and almost took her life. Dr, Buffington has over 35 years of experience as an expert witness in health care law pertaining to Clinical and Forensic Pharmacology and Toxicology and health care practice management. One evening in Thousand Oaks, California, life took a tragic turn after Bryn started her career as a Doctor of Audiology at UCLA. Bryn experimented with cannabis, unaware of its potential dangers. Unbeknownst to her, she inhaled a large hit of highly potent THC, which triggered a rapid descent into psychosis. In her altered state, her perception of reality was severely distorted, leading her to react to intense hallucinations. In a frantic attempt of fear, Bryn grabbed a kitchen knife, resulting in violence toward her dog, her friend Chad, and herself. When the police arrived, Bryn could not respond to the police commands; she was only responding to the internal commands, the voices in her head that instructed her to keep going. The court later ruled the incident as involuntary manslaughter, recognizing that cannabis-induced psychosis caused this tragic event. This heartbreaking story serves as a stark reminder of the potential dangers of cannabis use; it proves that a single use of cannabis can come to such a horrific end. Every Brain Matters extends its heartfelt sympathy to the friends and family of Chad O'Melia and Bryn Spejcher. Had either Chad or Bryn known this could happen from only using THC, this tragedy could have been prevented. This story proves that we need more awareness about the harms of cannabis use.To schedule a presentation from Bryn and learn more about cannabis-induced psychosis, CIP contact us at info@everybrainmatters.orgVisit https://everybrainmatters.orgLearn more about cannabis linked to violencehttps://everybrainmatters.org/thc-psychosis-and-violence/https://everybrainmatters.org/cannabis-science/marijuana-violence/Support the show@EveryBrainMatters

A new episode of Diabetes Day by Day is here! Join Drs. Neil Skolnik and Sara Wettergreen as they delve into the topic of heart failure. They'll discuss steps you can take if you're living with diabetes to prevent it or detect it early, and receive timely treatment for better outcomes.  In this episode, we welcome guest Jim Januzzi, MD, Professor of Medicine at Harvard Medical School, Cardiologist at Massachusetts General Hospital, and Chief Scientific Officer at the Baim Institute for Clinical Research. Dr. Januzzi has published more than 900 manuscripts, edited 5 textbooks, and serves as a Deputy Editor at the Journal of the American College of Cardiology. He is a nationally recognized lecturer on the testing and treatment of heart failure. Dr. Januzzi will share valuable insights to help people living with diabetes, no matter where they are in their journey, as it relates to heart health and heart failure.  This episode of Diabetes Day by Day is supported by Roche. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health, Abington, PA Sara Wettergreen, PharmD, BCACP, BC-ADM, Assistant Professor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences; and Ambulatory Care Clinical Pharmacist, UCHealth Lone Tree Primary Care, Aurora, CO Jim Januzzi, MD, Professor of Medicine at Harvard Medical School, Cardiologist at Massachusetts General Hospital, and Chief Scientific Officer at the Baim Institute for Clinical Research Do you have questions or comments you'd like to share with Neil and Sara? Leave a message at (703) 755-7288. Thank you for listening, and don't forget to “follow” Diabetes Day by Day!  

In this exciting episode of the Pediatric Pharmacist Review Podcast, we're diving into the fascinating world of pharmacogenomics and its transformative impact on pediatric care. Our special guest is Dr. Kelly E. Caudle, Pharm.D., Ph.D., FCCP, an Associate Member in the Department of Pharmacy and Pharmaceutical Sciences at St. Jude Children's Research Hospital. Dr. Caudle brings a wealth of expertise to the discussion, with over a decade of experience in pharmacogenomics implementation. As the Director of the NIH-funded Clinical Pharmacogenetics Implementation Consortium (CPIC), she oversees groundbreaking work in translating genetic test results into actionable prescribing decisions. With CPIC publishing 28 gene-based clinical guidelines covering 29 genes and over 150 drugs, Dr. Caudle's leadership is reshaping personalized medicine for children worldwide. Tune in as we explore how pharmacogenomics is enabling tailored treatments for pediatric patients, improving medication efficacy, and minimizing adverse effects. Dr. Caudle also shares insights into her work at St. Jude Children's Research Hospital and offers a glimpse into the future of personalized pediatric care. Key Takeaways: What pharmacogenomics is and why it matters for pediatric medicine. How CPIC guidelines are helping clinicians make data-driven prescribing decisions. The role of genetic testing in improving medication safety and outcomes for children. Dr. Caudle's journey in leading pharmacogenomics research and clinical implementation. Guest Bio: Dr. Kelly E. Caudle is a leading expert in pharmacogenomics, with over 100 publications and abstracts to her name. Her work has advanced the clinical implementation of pharmacogenetics at St. Jude Children's Research Hospital and beyond. As a passionate researcher and educator, she has inspired countless professionals through her national and international presentations.

In this episode of BioTalk with Rich Bendis, Dr. Eric Edwards, Co-Founder and CEO of MedPhlow, shares how his innovative company is reshaping emergency medicine through cutting-edge drug delivery systems. Dr. Edwards discusses his journey from co-founding Kaléo, where he helped develop life-saving products like AUVI-Q, to leading MedPhlow, a subsidiary of Phlow Corp. Based in Richmond, VA, MedPhlow is dedicated to addressing critical challenges in essential medicine delivery, with its first product focused on improving outcomes during sudden cardiac arrest. Dr. Edwards explains the groundbreaking technology behind MedPhlow's platform and how it is poised to transform emergency care. He also highlights the impact of investor partnerships, such as those with Virginia Venture Partners, and discusses MedPhlow's next milestones in its mission to make emergency medicine more efficient and accessible. As a part of the BioHealth Capital Region, Dr. Edwards reflects on the advantages of being based in this vibrant hub of innovation and his contributions as a BioHealth Innovation (BHI) board member. Tune in to learn about the future of MedPhlow and the inspiring work being done to advance life-saving solutions in healthcare. Editing and post-production work for this episode was provided by The Podcast Consultant (https://thepodcastconsultant.com). Dr. Edwards was previously co-founder of Kaléo, Inc. a pharmaceutical company in Richmond, VA. During his 16 years at Kaléo, he held several executive management positions including Chief Science Officer where he was responsible for overall scientific strategy and all pharmaceutical development programs; Chief Medical Officer responsible for developing a medical affairs team and capability while operationalizing the Company's clinical program strategy; and Vice President – Innovation, overseeing Kaleo's research and development pipeline and overall new product strategy.   Dr. Edwards is the co-inventor of multiple marketed products, including AUVI-Q, epinephrine auto-injector for the treatment of allergic emergencies (anaphylaxis), is named on over 215 issued and patent-pending applications, and is a published author on numerous scientific publications.   Dr. Edwards also continues to serve his community by volunteering on a local rescue squad, including responding to 911 calls and training paramedics in pre-hospital emergency care. Dr. Edwards. obtained his B.S. in Biology, Ph.D. in the Pharmaceutical Sciences, and Doctor of Medicine degrees at Virginia Commonwealth University/Medical College of Virginia.  

Guest: Dr. Shankar Musunuri - Ocugen, Chairman, Chief Executive Officer, and Co-founder Website: www.ocugen.com Ticker: OCGN Bio: Dr. Shankar Musunuri is Chairman, CEO and Co-Founder of Ocugen. The company (NASDAQ: OCGN) is a publicly traded biotechnology company focused on discovery, development, commercialization of gene therapies, cell therapies, biologicals, and vaccines, based in Malvern, Pennsylvania. Dr. Musunuri transformed Ocugen from a start-up into a cutting-edge science-based biotech powerhouse with three distinct first-in-class platform technologies focused on ophthalmology with a first-in-class modifier gene therapy platform targeting rare as well as large blindness diseases, orthopedics with a regenerative cell therapy platform, and infectious diseases with an inhalation vaccine platform targeting Covid-19, flu, and a combination vaccine for both COVID-19 and flu. Ocugen anticipates launching products from these game-changing platform technologies within the next few years. The company's mission is to develop cutting-edge innovations for people with serious diseases and conditions with a commitment to ensuring global market access. Dr. Musunuri is a seasoned biotech veteran with 30+ years' experience advancing and commercializing a diverse portfolio of products. Prior to co-founding Ocugen in 2013, he held leadership roles at numerous companies ranging from large multinational biotechnology companies such as Wyeth and Pfizer, to novel start-up biotech companies. During his 15 years at Pfizer, he gained extensive product launch and life-cycle management experience including leading the Global Operations Team for Prevnar 13, the world's best-selling vaccine. Dr. Musunuri then founded Nuron Biotech, Inc., which grew into a commercial company in less than three years. Dr. Musunuri obtained his PhD in Pharmaceutical Sciences from the University of Connecticut—where he also received a Distinguished Alumnus Award. He also received an MBA from Duke University, where today he serves on the University's Innovation & Entrepreneurship Board of Advisors. Dr. Musunuri serves as both CEO and Chairman of the board of Ocugen. He has received numerous leadership awards including Most Admired CEO Award by Philadelphia Business Journal, the 2023 Healthcare Power 100 (ranked 22nd) in PA and the 2023 AAPI Power 100 (ranked 11th) in PA. He is also a Board Member of the Musunuri Family Foundation, a non-profit that provides college scholarships for high school students. Dr. Musunuri has a passion for addressing diseases and conditions which lack effective treatments. This commitment is reflected in Ocugen's mission of relentlessly pursuing courageous innovation on behalf of patients with unmet medical needs. About Ocugen, Inc. Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients' lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com --- Support this podcast: https://podcasters.spotify.com/pod/show/smartmoneycircle/support

Tim Ulbrich, YFP CEO, talks with the five recipients of the first YFP Gives scholarships. Summary This episode is filled with inspiration as we share the stories of the five winners of the first YFP Gives scholarship. Let this episode be a ray of sunshine amidst some of the cloudy skies plaguing the pharmacy profession. If the future is in the hands of these outstanding students and new practitioners, then the future is bright. In this episode, you'll meet:  Alyssa Falleni, clinical pharmacist who specializes in addiction treatment, HCV, and HIV and is currently working in HIV outpatient care at Hartford Healthcare Momitul Talukdar, who after working in the radiology department at a hospital, discovered her calling as a nuclear pharmacist. Momi currently works at PETNET in Cleveland, OH Perrigrine Garner, a pharmacy student at the University of Toledo with a passion for helping those in need and a dream of owning an independent pharmacy that caters to those with chronic medical conditions and disabilities Ruth Adeyemi, a fourth-year PharmD/MPH Nigerian International student at the University of Florida College of Pharmacy and College of Public Health and Health Professions, with a deep-rooted commitment to improving health outcomes in underserved communities, particularly in her home country, Nigeria. Ai Len Nguyen Phan, a Rutgers Industry Fellow at Roche Genentech in San Francisco, with a desire to work in medical affairs and give back to the pharmacy community through her mentorship to the Rutgers pharmacy students About Today's Guests Alyssa Falleni is a clinical pharmacist who specializes in addiction treatment, HCV, and HIV. After graduating from the University of Rhode Island, Alyssa went on to complete an ambulatory care residency at Hennepin Healthcare in Minneapolis, MN. Following residency, Alyssa completed a two-year VA Advanced Fellowship in Health Professions' Education, Evaluation, and Research (HPEER) at the VA in West Haven, Connecticut. She will be continuing her teaching with the Yale School of Medicine as she begins a new HIV specialty position with Hartford Healthcare. Momi Talukdar, MS, PharmD Candidate 2024 is a graduate of Northeast Ohio Medical University College of Pharmacy. She's an incoming nuclear pharmacist at PETNET in Cleveland, OH. Along with her passion for nuclear pharmacy, she loves teaching nuclear pharmacy as an adjunct faculty at University of Wisconsin LaCrosse. In her spare time, Momi enjoys watching new films and art shows and trying out local coffee shops. Ai Len (Aileen) Nguyen Phan is a second-year Rutgers Pharmaceutical Industry Fellow at Genentech, Inc. - Rare Blood Disorders Medical Science Liaison. She graduated from the University of Maryland, School of Pharmacy with her Pharm.D. and M.S. in Regulatory Sciences in 2023. She supported the US Medical Information & Communication Target Therapies teams during the first year of her fellowship. While Aileen has just recently started her industry career, she continues to give back to the pharmacy community through her mentorship to the Rutgers pharmacy students, such as supporting their scientific research on using artificial intelligence to assess oncology treatments. Perrigrine Garner, a non-traditional student, and mother of three amazing daughters, is currently a P4 at the University of Toledo's College of Pharmacy and Pharmaceutical Sciences. Perrigrine is passionate about advocating for people with disabilities, especially in healthcare, as she is also a person with physical disabilities. Upon graduation, her dream is to help advance inclusivity in her community by opening an independent pharmacy that caters to those with chronic medical conditions and disabilities.  Ruth Adeyemi, a fourth-year PharmD/MPH Nigerian International student at the University of Florida College of Pharmacy and College of Public Health and Health Professions. Her journey in pharmacy is fueled by a deep-rooted commitment to improving health outcomes in underserved communities, particularly in my home country, Nigeria. With this passion, she started The Compassionate Pharmacy Practice Project (TCPPP), a project dedicated to transforming the Nigerian pharmacy practice system. The goal is to ensure that Good Pharmacy Practice (GPP) and Compassionate Care are not just concepts but realities in both urban and rural areas, significantly improving health outcomes in these communities. While Ruth is Nigerian, her commitment to improving health equity in underserved communities extends beyond borders. She is dedicated to her goal of ensuring that all patients, regardless of their neighborhood and built environment, receive the patient-centered, optimal, and compassionate care they deserve. Mentioned on the Show YFP Gives Ruth Adeyemi LinkedIn Alyssa Falleni LinkedIn Perrigrine Garner LinkedIn Momitul Talukdar LinkedIn Ruth Adeyemi Links:  https://sarmlife.com/  Books [Mastering the Art of Blogging for Your Brand] [Mastering the Art of SEO for Brand Growth] [Book Bundle - Discounted Price for purchasing both books] YFP Disclaimer Subscribe to the YFP Newsletter Tim Ulbrich on LinkedIn YFP on Instagram YFP Facebook Group  

Welcome to This Week in Pharmacy where we touch base on Pharmacy Times Reports on "Community Pharmacy's Existential Question: Should you Chase Product Revenues or Service Margins by Troy Trygstag PharmD. We talk about the Ohio Capital article on PBMs skimming millions of dollars from tax-payers, and Forbes reports on Mark Cuban Cost Plus Drugs is disrupting the PBM contracts and their work with Blue Shield of California. Big time news!!  Let's talk about Wound Care on This Week in Pharmacy: William Padula, PhD from the Alfred E. Mann School of Pharmacy & Pharmaceutical Sciences and-or David G. Armstrong MD from the Keck School of Medicine of USC, are talking with Todd Eury on TWIRx about a recent proposal from Medicare is calling to  eliminate coverage of some of skin substitute therapies, and the potential serious health risks that many Americans will face by limiting them. Skin substitutes, made from donated amniotic tissue, greatly improve wound care outcomes and help patients avoid limb amputations—a procedure that can double the risk of death for diabetic patients. This Medicare proposal under consideration will deny coverage of over 200 skin substitutes and limit how doctors can properly treat patients will leave tens of thousands of Medicare beneficiaries without treatment.